May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.
HVTN 702 may not have proven an effective vaccine, but scientists still learned from the research.
Dec. 12, 2019: A lot of catchup to do before “Ending the HIV Epidemic”; the value of online HIV self-test distribution; viral suppression is about more than basic HIV treatment services; effect of hormone therapy on PrEP levels.
Sep. 5, 2019: An extra decade of "heart age"; stop grouping trans women with MSM; women often have anal cancer precursor lesions; hep C treatment success doesn't equal more risk behavior.
A chlamydia infection makes HIV acquisition more likely.
Experts Flummoxed By Conflicting New Data on STIs, HIV, and Long-Term Contraception in Sub-Saharan Africa
ECHO trial results and follow-up studies find unexpectedly low rates of some STIs among users of certain long-term hormonal contraceptives. They also find high HIV rates (unrelated to the contraceptives) that suggest considerable value for PrEP integration.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
June 20, 2019: Housing stability and HIV viremia; how the stigma of poverty affects viral load; the best time to employ syringe services; promise for the practice of index testing.
No meaningful difference was found in either injectable or implant birth control when compared to an IUD.
Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.